<DOC>
	<DOCNO>NCT00028743</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give drug different combination may kill tumor cell . It yet know combination chemotherapy regimen effective treat ovarian epithelial , primary peritoneal , fallopian tube cancer . PURPOSE : Randomized phase III trial compare effectiveness different combination chemotherapy regimens treat patient stage IIB , stage III , stage IV ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer .</brief_summary>
	<brief_title>Comparison Combination Chemotherapy Regimens Treating Newly Diagnosed Ovarian Epithelial Cancer , Primary Peritoneal Cancer , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy cisplatin topotecan follow paclitaxel carboplatin v paclitaxel carboplatin , term time disease progression , patient newly diagnose stage IIB-IV ovarian epithelial , primary peritoneal , fallopian tube cancer . - Compare overall survival patient treat regimen . - Compare clinical objective response rate patient measurable disease baseline treat regimen . - Compare toxic effect regimens patient . - Compare CA 125 normalization rate patient treat regimen . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , age ( 65 year vs 65 year ) , pre-randomization surgery ( debulking v debulking macroscopic residual disease le 1 cm v debulking macroscopic residual disease 1 cm great v debulking macroscopic residual disease ) . Patients randomize one two treatment arm . - Arm I : Patients receive cisplatin IV 60 minute day 1 topotecan IV 30 minute day 1-5 course 1-4 paclitaxel IV 3 hour carboplatin IV 30 minute day 1 course 5-8 . - Arm II : Patients receive paclitaxel IV 3 hour carboplatin IV 30 minute day 1 course 1-8 . In arm , course repeat every 21 day absence disease progression unacceptable toxicity . Planned interval debulking surgery occur course 3 4 . Quality life assess baseline ; day 1 course 3 , 5 , 7 ; end last course ; 3 6 month study treatment completion . Patients follow every 3 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 800 patient ( 400 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIBIV ovarian epithelial , primary peritoneal , fallopian tube cancer No borderline ovarian tumor Residual disease allow Fine needle aspiration show adenocarcinoma allow instead open truecut biopsy follow true : Presence pelvic mass AND Omental cake metastasis large 2 cm upper abdomen unless proven stage IV disease AND Serum CA 125/carcinoembryonic antigen ratio least 25 ( less 25 , barium enema colonoscopy gastroscopy radiological examination stomach negative primary tumor within 6 week study ) AND Normal mammography within 6 week study PATIENT CHARACTERISTICS : Age : 18 75 Performance status : ECOG 01 Life expectancy : At least 12 week Hematopoietic : Granulocyte count least 2,000/mm^3 Platelet count least 150,000/mm^3 Hepatic : Not specify Renal : Creatinine great upper limit normal Cardiovascular : No clinically relevant atrial ventricular arrhythmia No myocardial infarction ( MI ) within past 6 month ( pretreatment ECG evidence MI allow ) No history second thirddegree heart block unless pacemaker implant History firstdegree heart block allow Other : Not pregnant nursing Fertile patient must use effective contraception No complete bowel obstruction No prior allergic reaction drug contain Cremophor EL compound chemically relate study drug No condition would preclude highvolume saline diuresis No significant neurologic psychiatric disorder would preclude study compliance No active uncontrolled infection No neuropathy great grade 1 No preexist hear loss great grade 1 No concurrent serious illness medical condition would preclude study participation No malignancy within past 5 year except adequately treat nonmelanoma skin cancer curatively treat carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biological response modifier immunotherapy No concurrent prophylactic colonystimulating factor ( CSFs ) Concurrent therapeutic CSFs allow Chemotherapy : No prior chemotherapy ovarian cancer No concurrent cytotoxic agent Endocrine therapy : No concurrent anticancer hormonal therapy Radiotherapy : No prior radiotherapy ovarian cancer Surgery : No 6 week since prior plan prechemotherapy surgery ovarian cancer Planned interval debulking allow Concurrent secondlook surgery allow Other : No prior nonsurgical therapy ovarian cancer No concurrent investigational drug therapy No concurrent anticancer treatment Concurrent enrollment CANNCICOV13/EORTC 55971 allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>